SCHEMBL7167366

SCHEMBL7167366

ON=C1CCCCC12CCCC2

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
CASP1 P29466 1/20 0.43
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7167365 1.00 TSHR (0.43) TSHRCASP1LMNA
SCHEMBL8432322 0.97 TSHR (0.48) TSHRCASP1LMNA
SCHEMBL9965954 0.77 SIGMAR1 (0.33)
SCHEMBL1353096 0.75 TSHR (0.40) TSHRCASP1LMNA
SCHEMBL1353098 0.75 TSHR (0.40) TSHRCASP1LMNA
SCHEMBL9963291 0.72 CHRNA7 (0.52)
SCHEMBL11486086 0.70 TSHR (0.36) TSHRCASP1LMNA
SCHEMBL11165836 0.70 TSHR (0.36) TSHRCASP1LMNA
SCHEMBL11459056 0.70 TSHR (0.36) TSHRCASP1LMNA
SCHEMBL11165834 0.70 TSHR (0.36) TSHRCASP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229072-A1 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binning agents BULLOCK WILLIAM H (US) 2003-12-11 US disclosed
EP-1317456-A2 CYCLIC AND ACYCLIC AMIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS Bayer Corporation (US) 2003-06-11 EP disclosed
WO-2002020526-A2 CYCLIC AND ACYCLIC AMIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229072-A1 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binning agents PGR, PGRMC1, PGRMC2 TSHR 108/4885CASP1 4559/4885LMNA 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.